Evaluation of the Protection Activity of Microfine Titanium Dioxide (Ti02), Pigmentary Ti02 and Bisoctrizole and Their Combinations in Voluntary Patients With Idiopathic Solar Urticaria (SU)

Idiopathic Solar Urticaria Clinical Trial

Official title: Evaluation of the Protection Activity of Microfine Ti02, Pigmentary Ti02 and Bisoctrizole and Their Combinations in Voluntary Patients With SU: Phase II Photoprovocation Test

Status Completed

Clinical Trial Summary

Commercially available external photoprotectors (EP) do not provide adequate protection against ultraviolet A (UVA) and visible wavelengths. The proposed medicinal product V0096 CR (formula RV3131A-MV1166) is a broad spectrum EP (bsEP). The rationale for the use of V0096 CR (formula RV3131A-MV1166) in the proposed condition is based on its ability to broadly block the UVA radiations and visible light that are known to trigger solar urticaria (SU).

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Idiopathic Solar Urticaria
• Urticaria

• NCT number: NCT00483496
• Study type: Interventional
• Source: Orfagen
• Status: Completed
• Phase: Phase 2
• Start date: September 2007
• Completion date: April 2008